Search
XTL-001
go.drugbank.com/drugs/DB05405InvestigationalXTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected
BMS-564929
go.drugbank.com/drugs/DB07286ExperimentalSo far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
PPI-2458
go.drugbank.com/drugs/DB05864InvestigationalClinical development with previous fumagillin derivatives has been limited by their toxicity profile.
Adinazolam
go.drugbank.com/drugs/DB00546ExperimentalIt has never been approved by the FDA for clinical use.
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
EGT-101
go.drugbank.com/drugs/DB17645ExperimentalDeveloped by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919]
Rhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis . It is known to have hepatoprotective, neph...
Thrombomodulin Alfa
go.drugbank.com/drugs/DB05777ApprovedThrombomodulin Alfa is a novel, recombinant and soluble thrombomodulin (ART-123). It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting...